Event-driven HIV prevention pill for men who have sex with men
Part of Immune system & allergy, Infections clinical trials.
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were assigned male at birth and are at least 18 years old.
- You have sex with men.
- You had condomless anal sex with men within the last month, and you can usually plan when you'll have sex.
- You've done at least one of these in the last 6 months: had anal sex without a condom with 2 or more partners, had a sexually transmitted infection (like chlamydia, gonorrhea, or syphilis), exchanged money or goods for sex, or used recreational drugs (not injected) or drank heavily.
- You are not currently taking HIV prevention medicine, but you may have taken it in the past (as long as it wasn't a long-acting form in the last 2 years).
- You test negative for HIV and do not have hepatitis B.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
This study tests a '2-1-1' on-demand PrEP strategy for cisgender men who have sex with men. It aims to see if taking PrEP only around the time of sex is safe and effective. If you are interested in starting or currently taking PrEP this way, you may be eligible.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
This study looks at how well a daily HIV prevention pill (F/TAF) works for people who use drugs. It also includes interviews with healthcare providers and peer navigators to understand how to better support patients.
This study tests different ways of taking HIV prevention medicine (PrEP) for men who travel for work in sub-Saharan Africa. It compares daily pills, pills only around sex, and a long-acting injectable to see which method works best and is easiest to use.
Hear when a new HIV/AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.